Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GSK acquires rights to Eusa’s preclinical antibody
As part of the agreement Eusa will pay approximately 50% of the overall consideration to its development partner for the antibody, Vaccinex. GSK will fund and conduct all
As part of the agreement Eusa will pay approximately 50% of the overall consideration to its development partner for the antibody, Vaccinex. GSK will fund and conduct all
The share of generic drugs in the US prescription drug market has reportedly increased from 40% to 58% during 2000-2006. With significant number of drugs like the Merck
The ElDorado Donor release is the company’s next generation software and is intended as a comprehensive blood management software application created to provide for the information system needs
The NPP is a compassionate use drug supply program administered by the Korea Orphan Drug Center (KODC) under which medical practitioners can legally supply investigational drugs to their
The round was led by vSpring Capital; other investors include Invitrogen, Epic Ventures (Formerly Wasatch Venture Fund), Toucan Capital, University of Utah Research Foundation, Salt Lake Life Science
Under terms of the agreements, the company will sell 7.5 million shares of its common stock at $0.50 per share. As part of the transaction, the investors also
Rechargeable neurostimulators are designed with a battery reserve to protect the device from damage should a patient discontinue therapy. The Eon neurostimulator’s battery reserve allows the device to
David Brown, LifeVantage’s president and CEO, said: “NutraNomics has strong relationships with Mitsui Busan, Watakura, and Kanebo, through which the company distributes products in the Asian retail sector.”
The consortium will investigate new human immunodeficiency virus (HIV) antigen formulations for triggering broadly neutralizing antibodies in the blood and mucosal compartments, using various adjuvants and platform technologies
The company will also rename the business Therapeutic Support Systems to better reflect the clinical value its therapies offer to caregivers and patients. Lynne Sly, who recently served